were also transduced. Intravenous administration of scAAV2/9 to late gestation fetal macaques also produced widespread gene delivery and confi rmed our observations in the mice. We, and others, have shown that systemic administration of AAV2/9 crosses the blood-brain barrier and mediates effi cient gene delivery to the nervous system. The data presented here highlights the promise that this vector shows for treating systemic diseases that are perinatal lethal and affect both the brain and the viscera.
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Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno-Associated Virus (AAV)2 Capsid Improves Its Transduction Effi ciency It is now well recognized that hepatic gene transfer of high doses of AAV vectors predispose to a robust adaptive immune response, from the data available from hemophilia clinical trials. Thus there is a need to develop novel strategies which will allow lower doses of vectors to be used to achieve sustained phenotypic correction and limit vector related immune-toxicities. Previous studies have demonstrated the utility of mutating surface-exposed tyrosine residues on AAV2 capsid which possibly protects the vector particles from ubiquitin-mediated proteasome degradation and resulted in a signifi cant increase in transgene expression (Zhong et al, 2008) . We hypothesized that mutations at lysine residues of AAV2 common capsid region, VP3, which are direct targets for host ubiquitin ligases, will improve its transduction effi ciency. Our in silico analysis using an ubiquitination prediction software (UbPred, http://www.ubpred. org/) identifi ed seven lysine residues (K39, K137, K143, K161, K490, K527 and K532) on AAV2 capsid which could be potentially ubiquitinated. Lysine>Arginine mutations in AAV2 Rep/Cap coding plasmid was carried out and highly purifi ed stocks of a recombinant self-complementary AAV2 vectors expressing EGFP [scAAV-CBa-EGFP] were generated in each of the seven mutant plasmids. The physical particle titres of lysine mutant vectors was comparable to wild-type (WT) scAAV vectors (∼0.5-1 X 10^12 vgs/mL), suggesting that these mutations do not affect the structure or packaging ability of mutant capsids. scAAV vectors containing WT or each of the seven lysine mutant capsids were then evaluated for their transduction potential in vitro. Approximately 8 X 10 4 HeLa or HEK293 cells were mock-infected or infected with AAV at different multiplicities of infection (MOI, 500, 2000 or 5000 vgs/cell). Forty-eight hours post-infection, transgene (EGFP) expression was measured by fl uorescence microscopy and by fl ow-cytometry. Our results (Fig. 1 ) demonstrate that one of the seven mutants tested, the K532R vector, signifi cantly increased gene expression in both HeLa (18X) and HEK 293 (9X) cells in vitro in comparison to WT-AAV2. This increased transduction effi cacy of the K532R vector was consistent across three different MOIs tested, with an average increase of 10-fold over the WT vector. Further ongoing studies in normal and hemophilia B mice will demonstrate if the AAV2 K532R vector can also improve hepatic gene transfer, in vivo. Recombinant adenoviruses (Ads) are amongst the most effi cient hepatotropic gene delivery vehicles, but a drawback of their use is transient transgene expression and toxicity resulting from induction of host immune responses. To limit vector immunostimulation, we have generated RNAi-activating anti-HBV gutless helper-dependent (HD) Ads. Effi cacy against HBV replication was tested in HBV transgenic mice, which stringently simulate the human condition of chronic HBV infection. Two days after intravenous administration of 5×109 recombinant HD Ads to HBV transgenic mice, 80-90% of hepatocytes were transduced. Markers of HBV replication were decreased by approximately 95% in animals receiving the HD Ads and this effect was sustained for 8 weeks without adverse effects. Compared to unmodifi ed fi rst generation anti-HBV Ads, inhibition of viral replication was signifi cantly more sustained. Moreover, acute hepatotoxicity and proinfl ammatory cytokine release following administration of HD Ads was attenuated. HD Ad DNA was present at high concentrations in the livers of mice at termination of the investigation, which indicates that diminished effi cacy was a result of switching off of transgene expression rather than elimination of the vector from hepatocytes. Alternative transcription control elements, reduction of immunostimulation by pretreatment with dexamethasone and polymer modifi cation are being investigated to improve delivery of anti-HBV RNAi activators by these vectors.
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